- Home
- YAAS vs SGHT Comparison
YAAS vs SGHT Comparison
Compare YAAS & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YAAS
- SGHT
- Stock Information
- Founded
- YAAS 2018
- SGHT 2011
- Country
- YAAS China
- SGHT United States
- Employees
- YAAS N/A
- SGHT N/A
- Industry
- YAAS Computer Software: Prepackaged Software
- SGHT Medical Specialities
- Sector
- YAAS Technology
- SGHT Health Care
- Exchange
- YAAS Nasdaq
- SGHT Nasdaq
- Market Cap
- YAAS 265.0M
- SGHT 304.4M
- IPO Year
- YAAS 2024
- SGHT 2021
- Fundamental
- Price
- YAAS N/A
- SGHT $3.54
- Analyst Decision
- YAAS
- SGHT Buy
- Analyst Count
- YAAS 0
- SGHT 7
- Target Price
- YAAS N/A
- SGHT $6.27
- AVG Volume (30 Days)
- YAAS 57.0
- SGHT 234.0K
- Earning Date
- YAAS 01-01-0001
- SGHT 11-07-2024
- Dividend Yield
- YAAS N/A
- SGHT N/A
- EPS Growth
- YAAS N/A
- SGHT N/A
- EPS
- YAAS N/A
- SGHT N/A
- Revenue
- YAAS $774,333.00
- SGHT $79,543,000.00
- Revenue This Year
- YAAS N/A
- SGHT $2.18
- Revenue Next Year
- YAAS N/A
- SGHT $8.14
- P/E Ratio
- YAAS N/A
- SGHT N/A
- Revenue Growth
- YAAS N/A
- SGHT N/A
- 52 Week Low
- YAAS $3.48
- SGHT $3.16
- 52 Week High
- YAAS $4.50
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- YAAS N/A
- SGHT 36.40
- Support Level
- YAAS N/A
- SGHT $3.52
- Resistance Level
- YAAS N/A
- SGHT $3.73
- Average True Range (ATR)
- YAAS 0.00
- SGHT 0.20
- MACD
- YAAS 0.00
- SGHT 0.01
- Stochastic Oscillator
- YAAS 0.00
- SGHT 24.54
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.